Aims: In patients with heart failure, over-activation of the cardiac sympathetic nerve (CSN) function is associated with severity of heart failure and worse outcome. The effects of MitraClip therapy on the CSN activity in patients with mitral regurgitation (MR) remained unknown. In this study, we evaluated the impact of the MitraClip therapy on CSN activity assessed by I-metaiodobezylguanidine (MIBG) scintigraphy.

Methods And Results: We enrolled consecutive patients with moderate-to-severe (3+) or severe (4+) MR who were scheduled to undergo MitraClip procedure in this prospective observational study. MIBG scintigraphy was performed at baseline and 6 months after the MitraClip procedure to evaluate the heart-mediastinum ratio and washout rate (WR). Changes in these MIBG parameters were analysed. Of the 13 consecutive patients, 10 were successfully treated with MitraClip procedure and completed follow-up assessment. With regard to the MIBG parameters, changes in the early and delayed heart-mediastinum ratio from baseline to 6 months were not significant (2.16 ± 0.42 to 2.06 ± 0.34, P = 0.38 and 1.87 ± 0.39 to 1.83 ± 0.39, P = 0.43, respectively), whereas WR was significantly decreased (38.6 ± 3.9% to 32.6 ± 3.94%, P = 0.002).

Conclusions: The CSN activity of the WR on MIBG imaging was improved 6 months after MitraClip therapy in patients with 3+ or 4+ MR.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006686PMC
http://dx.doi.org/10.1002/ehf2.13266DOI Listing

Publication Analysis

Top Keywords

mitraclip therapy
16
csn activity
12
mitraclip procedure
12
cardiac sympathetic
8
sympathetic nerve
8
heart failure
8
therapy csn
8
consecutive patients
8
baseline 6 months
8
6 months mitraclip
8

Similar Publications

Background: The transcatheter edge-to-edge repair (TEER) technique, facilitated by the MitraClip device, is a minimally invasive intervention designed for high-risk patients with mitral regurgitation (MR). This study conducts a retrospective analysis of death events associated with MitraClip implantation over a ten-year decade, utilizing data from the FDA's Manufacturer and User Facility Device Experience (MAUDE) database to evaluate trends in safety outcomes.

Methods: A comprehensive search of the publicly accessible MAUDE database was conducted to retrieve reports of deaths and injuries related to MitraClip implantation from October 2013 to September 2023.

View Article and Find Full Text PDF

With the emergence of less invasive transcatheter valvular therapies, there remains a limited understanding of the feasibility and durability of these approaches in patients with osteogenesis imperfecta and whether they can offer a suitable alternative to conventional surgery. In this context, and with a focus on mitral repair, we report on a case of mitral transcatheter edge-to-edge repair in a patient with osteogenesis imperfecta and conduct a comprehensive review of the characteristics and outcomes of reported osteogenesis imperfecta cases undergoing surgical or transcatheter mitral repair. Given the high burden of complications of surgery in this population, transcatheter mitral repair could potentially serve as a suitable alternative to conventional surgery in this challenging population.

View Article and Find Full Text PDF

Meta-analysis of MitraClip and PASCAL for transcatheter mitral edge-to-edge repair.

J Cardiothorac Surg

January 2025

Department of Internal Medicine II, Städtisches Klinikum Solingen, Solingen, Germany.

Article Synopsis
  • The study compares the safety and efficacy of the MitraClip and PASCAL systems for treating mitral regurgitation (MR), finding limited differences.
  • A total of eight studies involving 1,612 patients were analyzed, showing no significant variation in MR severity reduction between the two devices.
  • Both devices demonstrated similar safety and procedural success, though PASCAL showed a slight trend toward better MR reduction, but without statistically significant results.
View Article and Find Full Text PDF

Transjugular transcatheter edge-to-edge mitral valve repair in a patient with functional mitral regurgitation: a case report.

Eur Heart J Case Rep

January 2025

Department of Cardiovascular Medicine, Sendai Kousei Hospital, 1-20 Tsutsumidori-amamiya, Aoba Ward, Sendai, Miyagi 9810914, Japan.

Article Synopsis
  • The transcatheter edge-to-edge mitral valve repair (M-TEER) using the MitraClip system is usually done via the transfemoral approach, but the transjugular approach can be a viable alternative when the former isn't possible.
  • A 57-year-old man with heart failure and severe functional mitral regurgitation could not undergo the transfemoral approach due to an occluded inferior vena cava, leading to the decision to use the transjugular technique instead.
  • The procedure was successful with no complications, significantly reducing the patient's mitral regurgitation, and he showed sustained improvement a year later.
View Article and Find Full Text PDF

Background: Acute type A aortic dissection (A-AAD) with severe acute aortic regurgitation (AR) and coronary involvement is a potentially fatal condition that causes left ventricular volume overload and catastrophic acute myocardial infarction. We present the successful management of a patient using Impella 5.5 following cardiopulmonary arrest caused by A-AAD with severe acute AR and left main trunk (LMT) obstruction.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!